Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism

Fig. 1

Synthetic origin of CAD-31. CAD-31 was derived from curcumin by following a series of synthetic steps described in the text and outlined here. The selections of CNB-001, CNB-023, and J147 (steps A, B, and C in the figure) were all done on the basis of improved potency in the neurotoxicity assays shown in Table 1. The final step (D) needed to generate CAD-31 was done by selecting the most potent compound in a 230-compound J147 library using a human cell-based neurogenesis assay [4]

Back to article page